# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...
JMP Securities analyst Reni Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and lowers the...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...
On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for fro...
Response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïv...